Gender differences in viral load by CD4 count in men and women

HIV Treat Bull - 2008 May-June;9(5/6):15

Polly Clayden, HIV i-Base

Previous research has found that CD4 count-adjusted viral load is approximately 0.2 log copies/mL greater in men compared to women. But these data have been largely limited to industrialised countries.

The PEARLS study of the ACTG (a randomised clinical trial of antiretroviral efficacy) provided an opportunity to compare men and women with CD4 <300 cells/mm³ prior to initiation of antiretroviral therapy (ART) from 8 resource-limited countries and the United States.

A poster authored by Beatriz Grinsztejn and coworkers from the PEARLS study team showed findings from a comparison of characteristics of men and women with advanced HIV in Africa, Asia, the Caribbean and North and South America. The aim was to assess whether gender-associated differences in viral load are constant in diverse HIV-positive populations.

This comparison enrolled 1571 (831 men and 740 women) drug naïve (no more than 7 days of culmulative prior therapy) patients.

The investigators reported that within 45 days prior to ART initiation, compared to women, men were older, had lower body mass index, platelet and CD4 counts, but higher albumin, hemoglobin, and creatinine clearance (p<0.001 for all comparisons).

Table 1: Men vs women difference in viral load by CD4 count adjusted for ethnicity, country and history of AIDS

The investigators noted that prior antiretroviral use did not explain lower viral loads in women: in this study only 8.2% women reported any previous use (largely single dose NVP) and only 4.7% had more than 7 days previous antiretroviral exposure.

The investigators concluded: “Our analyses suggest that gender-associated viral load differences are more likely to be associated with inherent biological differences in men and women than with factors linked to geographic location including race, co-infections, culture, or environment.”

Ref: Grinsztejn B, Smeaton L, De Gruttola V et al. Gender-associated differences in pre-ART plasma HIV-1 RNA in diverse areas of the world vary by CD4+ cell count. Conf Retroviruses Opportunistic Infect. 2008 Feb 3-6;15: Poster abstract 672.

2008-05-10
IB080905-11

©2008. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.